Cardiff Oncology, Inc.

https://www.cardiffoncology.com

Cardiff Oncology, Inc. is a clinical-stage biotechnology company dedicated to developing novel therapeutic options for cancer patients. Headquartered in San Diego, California, the company's core mission revolves around leveraging Polo-like Kinase 1 (PLK1) inhibition to create innovative therapies that address significant unmet medical needs across various cancers.

The company's lead asset is onvansertib, an oral and selective PLK1 inhibitor. Cardiff Oncology is evaluating onvansertib in combination with standard-of-care (SoC) therapeutics across multiple clinical programs. These programs target indications such as RAS-mutated metastatic colorectal cancer (mCRC), metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple-negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). The development strategy aims to target tumor vulnerabilities, overcome treatment resistance, and deliver superior clinical benefits compared to existing SoC treatments.

In recent leadership changes, Mani Mohindru was appointed President and Chief Executive Officer in April 2026, having served as interim CEO since January 2026. Josh Muntner joined as Chief Financial Officer and Ajay Aggarwal as Chief Operating Officer in April 2026. Cardiff Oncology announced in April 2026 that it would present updated data from its CRDF-004 Phase 2 clinical trial at the American Society of Clinical Oncology (ASCO) Annual Meeting. This trial investigates onvansertib in first-line RAS-mutated mCRC, building on previous positive updates that demonstrated robust objective response rates and improved progression-free survival. The company reported positive full-year 2025 results in February 2026, emphasizing strong clinical momentum for onvansertib, and plans to engage with the FDA in the first half of 2026 to discuss a registrational program for the drug in RAS-mutated mCRC.

Latest updates

Cardiff Oncology Highlights Onvansertib Data with KOL Webinar

Event summary

  • Cardiff Oncology will host a webinar on April 30, 2026, featuring KOL Mrinal Patnaik.
  • The webinar will focus on data from an investigator-initiated trial of onvansertib as a single agent in chronic myelomonocytic leukemia (CMML).
  • Mrinal Patnaik leads the Acute Leukemia and Myeloid Neoplasms group and Epigenomics Program at Mayo Clinic.
  • Onvansertib is Cardiff Oncology’s lead asset, a PLK1 inhibitor currently in Phase 2 trials for mCRC.

The big picture

Cardiff Oncology’s focus on PLK1 inhibition represents a targeted approach to cancer treatment, aiming to overcome resistance mechanisms. The webinar highlights the company’s efforts to expand onvansertib’s application beyond its primary mCRC indication, a common strategy for clinical-stage biotech firms seeking to broaden market opportunity and de-risk their pipelines. The reliance on KOLs to present data underscores the importance of external validation in the competitive oncology landscape.

What we're watching

Clinical Efficacy
The webinar’s data presentation will be crucial in assessing onvansertib’s potential beyond its current mCRC focus, particularly given its reported activity in hard-to-treat tumors.
KOL Influence
Mr. Patnaik’s prominence in myeloid neoplasms research suggests the webinar aims to bolster confidence in onvansertib’s clinical utility and potentially attract further investment.
Trial Adoption
The reliance on investigator-initiated trials indicates Cardiff Oncology’s strategy for expanding onvansertib’s indications, and the pace of enrollment and data maturation in these trials will dictate the drug’s broader development timeline.

Cardiff Oncology to Present Updated Data on RAS-Mutated Colorectal Cancer Treatment

Event summary

  • Cardiff Oncology will present updated Phase 2 data (CRDF-004 trial) at the ASCO 2026 Annual Meeting on June 2, 2026.
  • The trial evaluates onvansertib in combination with standard of care (FOLFIRI/bevacizumab or FOLFOX/bev) for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC).
  • The abstract (number 3510) will be publicly available on ASCO’s website starting May 21, 2026.
  • Onvansertib is a PLK1 inhibitor being investigated for multiple cancers, including mPDAC, SCLC, TNBC, and CMML.

The big picture

The presentation of CRDF-004 data represents a key inflection point for Cardiff Oncology, as it seeks to validate onvansertib's efficacy in a significant, underserved patient population. RAS mutations are increasingly recognized as a critical therapeutic target in mCRC, and the success of onvansertib could establish Cardiff Oncology as a player in this evolving oncology space. However, the mCRC market is highly competitive, with numerous other therapies in development, making the ASCO presentation and subsequent data analysis critical for investor sentiment and future strategic decisions.

What we're watching

Clinical Efficacy
The interim results presented at ASCO will be crucial in determining whether onvansertib demonstrates sufficient clinical benefit to warrant further development and potential regulatory approval, particularly given the competitive landscape in mCRC.
Regulatory Pathway
The strength of the ASCO data will heavily influence Cardiff Oncology’s strategy for engaging with regulatory agencies, potentially impacting the timeline and requirements for a potential Biologics License Application (BLA).
Competitive Dynamics
How the data is received relative to other emerging therapies targeting RAS mutations will shape Cardiff Oncology’s positioning and commercial prospects within the crowded mCRC treatment market.

Cardiff Oncology Data Suggests ADC Combination Could Broaden HER2-Low Breast Cancer Treatment

Event summary

  • Cardiff Oncology presented preclinical data at the 2026 AACR Annual Meeting demonstrating antitumor activity of onvansertib combined with trastuzumab deruxtecan (T-DXd).
  • The combination showed tumor regression in nearly all mice tested, with complete response rates up to 62% in HER2-low breast cancer models.
  • Data suggest the combination overcomes resistance to fulvestrant and CDK4/6 inhibitors.
  • Onvansertib is currently in Phase 2 clinical development for RAS-mutated metastatic colorectal cancer.

The big picture

The data highlights a potential shift in ADC treatment strategies, moving beyond targeted therapies to incorporate PLK1 inhibitors to overcome resistance and improve efficacy. This approach could broaden the applicability of ADCs to a wider range of cancers and patient populations, potentially impacting the $30+ billion ADC market. Cardiff Oncology's success here could validate the PLK1 inhibition strategy and open doors for similar combination approaches in other oncology areas.

What we're watching

Clinical Translation
The preclinical efficacy observed will need to be replicated in human clinical trials to validate the combination's potential.
Regulatory Pathway
Given the existing approvals for both onvansertib and T-DXd, the regulatory pathway for the combination may be accelerated, but will depend on clinical trial results.
Market Adoption
The success of this combination will hinge on its ability to address the significant unmet need in HER2-low breast cancer, a growing segment due to the limitations of existing therapies.

Cardiff Oncology Bolsters Leadership with CFO, COO Appointments

Event summary

  • Mani Mohindru, previously Interim CEO and Board member, has been appointed President and CEO of Cardiff Oncology.
  • Josh Muntner joins as Chief Financial Officer, effective April 6, 2026, bringing experience as CFO of Imvax and Mesoblast.
  • Ajay Aggarwal, MD, MBA, assumes the role of Chief Operating Officer, effective April 27, 2026, following roles at Aclaris and CereXis.
  • Cardiff Oncology granted non-qualified stock options (486,650 shares) to Josh Muntner as an inducement, with an exercise price of $1.58 per share.

The big picture

Cardiff Oncology's leadership overhaul signals a strategic push to accelerate the development of onvansertib, a PLK1 inhibitor targeting a significant unmet need in colorectal cancer. The appointments of a seasoned CFO and COO suggest a focus on operational efficiency and securing future funding, particularly as the company advances its clinical program. This restructuring comes as the broader biotech sector faces increased scrutiny regarding clinical trial outcomes and capital allocation.

What we're watching

Execution Risk
The success of Cardiff’s onvansertib program hinges on the newly assembled leadership team’s ability to navigate clinical development and regulatory hurdles efficiently.
Financial Stability
Given Josh Muntner’s experience, Cardiff will likely pursue additional financing rounds; the terms and timing of these will be critical to maintaining operational runway.
Clinical Progress
The Phase 2 trial data for onvansertib in first-line RAS-mutant metastatic colorectal cancer will be a key catalyst for the company’s valuation and future prospects.

Cardiff Oncology Highlights RAS Mutation Treatment Strategy in KOL Webinar

Event summary

  • Cardiff Oncology will host a webinar on March 25, 2026, featuring KOLs Scott Kopetz and Heinz-Josef Lenz.
  • The webinar will focus on the treatment landscape for first-line RAS-mutated metastatic colorectal cancer (mCRC).
  • The discussion will center on onvansertib, Cardiff Oncology’s lead asset, and its clinical data.
  • Mani Mohindru, interim CEO, will participate in the webinar.

The big picture

RAS mutations are increasingly recognized as a significant driver of colorectal cancer, representing a substantial unmet need in oncology. Cardiff Oncology's focus on PLK1 inhibition and onvansertib's potential in this area positions the company within a growing market segment. The KOL discussion serves as a strategic effort to shape the narrative around onvansertib and its role in the evolving treatment paradigm for mCRC.

What we're watching

Clinical Efficacy
The webinar's discussion of onvansertib's clinical data will be critical; positive reinforcement from leading experts could significantly impact investor sentiment and accelerate development timelines.
Competitive Landscape
The emergence of new therapies targeting RAS mutations will likely intensify competition in the mCRC space, potentially impacting onvansertib’s market share and pricing strategy.
Regulatory Pathway
The FDA’s acceptance of novel approaches to RAS-mutated cancers will dictate the speed of onvansertib’s approval and commercialization, and the KOL discussion may provide insights into potential hurdles.

Cardiff Oncology Data Suggests Potential Synergy with Roche's T-DXd

Event summary

  • Cardiff Oncology will present preclinical data at the 2026 AACR Annual Meeting on April 19, 2026.
  • The data focuses on onvansertib, a PLK1 inhibitor, in combination with trastuzumab deruxtecan (T-DXd).
  • Findings indicate onvansertib enhanced T-DXd’s activity and reversed resistance in HER2-low breast cancer models.
  • Onvansertib is currently in Phase 2 clinical development for RAS-mutated metastatic colorectal cancer (mCRC).

The big picture

The combination of targeted therapies like onvansertib with existing antibody-drug conjugates (ADCs) like T-DXd represents a growing trend in oncology, aiming to overcome resistance and improve patient outcomes. This data suggests a potential avenue for Cardiff Oncology to expand its pipeline and potentially partner with larger pharmaceutical companies. The success of this combination will hinge on demonstrating a clinically meaningful benefit and navigating the complexities of co-commercialization or licensing agreements.

What we're watching

Clinical Validation
The upcoming AACR presentation's data will be crucial in determining if the preclinical synergy between onvansertib and T-DXd translates to meaningful clinical benefit in human trials, particularly given the challenges in HER2-low breast cancer.
Commercial Implications
How Cardiff Oncology navigates potential partnerships or licensing agreements with Roche, the manufacturer of T-DXd, will significantly impact the commercial viability of onvansertib in HER2-low breast cancer.
Pipeline Expansion
The pace at which Cardiff Oncology expands onvansertib’s investigation into other cancers beyond its lead indication of mCRC will depend on the success of ongoing investigator-initiated trials and the availability of funding.

Cardiff Oncology Schedules Investor Roadshow Amid Clinical Trial Scrutiny

Event summary

  • Cardiff Oncology will present at three investor conferences in March 2026: TD Cowen, Barclays, and Leerink Partners.
  • The conferences will be held between March 4th and March 11th, 2026.
  • Cardiff Oncology's lead asset, onvansertib, is in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC).
  • The company is leveraging PLK1 inhibition to develop cancer therapies, targeting a validated oncology target.

The big picture

Cardiff Oncology's aggressive investor roadshow signals a period of heightened scrutiny for the company, particularly given the high-risk nature of clinical-stage biotechnology and the competitive landscape within oncology. The company's reliance on onvansertib and its Phase 2 trial results makes it vulnerable to both positive and negative data releases. These conferences provide a key venue for management to shape the narrative and address investor concerns.

What we're watching

Clinical Data
The content and reception of management's presentations at these conferences will likely hinge on emerging data from the Phase 2 mCRC trial, which will be scrutinized for efficacy and safety signals.
Investor Sentiment
The frequency of investor conference appearances suggests a proactive effort to manage expectations and potentially counter any negative sentiment arising from clinical trial uncertainties or competitive pressures.
Pipeline Expansion
The company's ability to articulate a clear path for expanding onvansertib's application beyond mCRC will be crucial for sustaining investor interest and justifying its current valuation.

Cardiff Oncology Data Bolsters First-Line CRC Program, Signals Registrational Path

Event summary

  • Cardiff Oncology reported a Phase 2 trial (CRDF-004) showing a 72.2% objective response rate (ORR) with onvansertib + FOLFIRI/bev in first-line RAS-mutated mCRC, compared to 43.2% with standard of care.
  • The trial demonstrated a statistically significant improvement in progression-free survival (HR: 0.37, p<0.05) with the onvansertib combination.
  • Cardiff Oncology appointed Mani Mohindru as interim CEO and Brigitte Lindsay as Chief Accounting Officer in January 2026, amidst a search for permanent executive leadership.
  • The company ended 2025 with $58.3 million in cash, projecting sufficient runway into Q1 2027.
  • Clinical data on onvansertib monotherapy in chronic myelomonocytic leukemia (CMML) were presented at ASH 2025, showing preliminary efficacy in approximately 40% of patients.

The big picture

Cardiff Oncology's Phase 2 data represent a potentially significant advancement in first-line treatment for RAS-mutated mCRC, a market with high unmet need and limited innovation in over two decades. The robust ORR and PFS improvements, coupled with the planned registrational program, position onvansertib as a potential new standard of care. However, the company's reliance on FDA approval and the ongoing executive leadership transition introduce key risks that investors must monitor.

What we're watching

Regulatory Approval
The FDA discussions and subsequent registrational plans will be critical to determining the timeline and likelihood of onvansertib's approval, which will significantly impact Cardiff's valuation.
Execution Risk
The transition to late-stage development and the search for a permanent CEO and CFO introduce execution risks that could delay the program or impact operational efficiency.
Competitive Landscape
The success of onvansertib will depend on its ability to maintain a competitive advantage over existing and emerging therapies in the RAS-mutated mCRC space, particularly given the established use of FOLFOX and FOLFIRI.

Cardiff Oncology to Detail PLK1 Strategy at Oppenheimer Conference

Event summary

  • Cardiff Oncology management, including Interim CEO Mani Mohindru, will present at the Oppenheimer Healthcare Life Sciences Conference on February 25, 2026.
  • The presentation will be a virtual event, accessible via webcast from Cardiff Oncology's website.
  • Cardiff Oncology's lead asset, onvansertib, is in Phase 2 trials for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC).
  • The company focuses on PLK1 inhibition, targeting a validated oncology target.

The big picture

Cardiff Oncology's focus on PLK1 inhibition represents a targeted approach to cancer treatment, aiming to address a significant unmet need in RAS-mutated colorectal cancer. The company's reliance on investigator-initiated trials, while demonstrating early activity, also introduces execution risk and potential delays in broader commercialization. The conference presentation provides a key opportunity to gauge investor confidence in the company's strategy and pipeline.

What we're watching

Clinical Progress
The conference presentation will likely detail progress in the Phase 2 mCRC trial; investor reaction will hinge on any data updates or shifts in trial design.
Leadership Stability
The presence of an Interim CEO (Mani Mohindru) suggests ongoing leadership transition; the conference offers a chance to assess the long-term strategic direction under his guidance.
Market Adoption
The success of onvansertib will depend on its ability to overcome treatment resistance in a market crowded with existing therapies; the conference may reveal insights into adoption strategies.

Cardiff Oncology's Onvansertib Shows Promise in First-Line mCRC Trial

Event summary

  • Cardiff Oncology’s Phase 2 trial (CRDF-004) showed dose-dependent improvements in overall response rates and progression-free survival (PFS) when onvansertib was added to FOLFIRI/bevacizumab in first-line RAS-mutated mCRC.
  • The 30mg dose of onvansertib combined with FOLFIRI/bevacizumab demonstrated the most favorable results, with a PFS HR of 0.37 (vs SoC) and an ORR of 72.2%.
  • The company plans to initiate a registrational program later in 2026, comparing onvansertib with FOLFIRI/bevacizumab to standard-of-care regimens.
  • Data suggest onvansertib was well-tolerated, with no major or unexpected toxicities observed.

The big picture

The Phase 2 data represent a significant advancement in the treatment of RAS-mutated mCRC, a patient population with limited therapeutic options. Onvansertib’s novel mechanism of action as a PLK1 inhibitor addresses a critical unmet need in oncology, potentially shifting the standard of care for this patient segment. The company's decision to move directly to a registrational trial underscores the perceived strength of the data and the potential for a rapid market entry.

What we're watching

Regulatory Approval
The success of the planned registrational trial will be critical for securing FDA approval and establishing onvansertib as a new standard of care, which hinges on the FDA’s consultation and acceptance of the trial design.
Competitive Landscape
The emergence of onvansertib as a potential first-line treatment could intensify competition within the mCRC market, potentially impacting the market share of existing therapies.
Commercialization
Cardiff Oncology's ability to successfully commercialize onvansertib, including securing reimbursement and establishing a robust sales infrastructure, will be key to realizing the drug’s full potential.
CID: 549